Product Information
RANOLAZINE ER 1,000 MG TABLET is a generic product labeled by Actavis Pharma, Inc., priced at $0.2824 per EA under NDC 45963041906. Its NADAC has been published 354 times since Aug 21, 2019.
FDA first approved this application on May 28, 2019.
The High Outlier badge above means this manufacturer's average price in the Ranolazine market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
1000 mg/1
Manufacturer
Actavis Pharma, Inc.NDC
45963041906
Classification
Generic
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Route
ORAL
Effective Date
5/20/2026
Active Ingredients
RANOLAZINEApproval Type
Generic (ANDA)
FDA Application
ANDA208862FDA Approved
5/28/2019
On Market Since
5/28/2019
Pharmacological Classes
Price Statistics
The NADAC for RANOLAZINE ER 1,000 MG TABLET has been published 354 times since Aug 21, 2019, and over the history we have for it it has declined 75.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2824 per EA |
|---|---|
| All-time high | $1.1472 (Oct 16, 2019) |
| All-time low | $0.2725 (Apr 22, 2026) |
| 52-week high | $0.3159 |
| 52-week low | $0.2725 |
| Median price | $0.3645 |
| Average price | $0.5051 |
| Largest weekly change | -21.2% (Mar 23, 2022) |
| Weeks tracked | 354 |
| Tracking since | Aug 21, 2019 |
1W
N/A
1M
N/A
3M
0.0%
6M
+2.4%
1Y
-10.6%
3Y
-13.7%
5Y
-56.8%
All
-75.4%
Last surveyed May 27, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 11 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 2% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of RANOLAZINE ER 1,000 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for RANOLAZINE ER 1,000 MG TABLET, manufactured by Actavis Pharma, Inc., is $0.2824 per EA (NDC 45963041906), effective May 27, 2026.
How has the price of RANOLAZINE ER 1,000 MG TABLET changed over time?
Over the history we have for it, the NADAC for RANOLAZINE ER 1,000 MG TABLET has declined 75.4%. It has been tracked across 354 weekly CMS publications since Aug 21, 2019.
What are the highest and lowest recorded NADAC prices for RANOLAZINE ER 1,000 MG TABLET?
Since Aug 21, 2019, the NADAC for RANOLAZINE ER 1,000 MG TABLET has ranged from a low of $0.2725 (Apr 22, 2026) to a high of $1.1472 (Oct 16, 2019), with a median of $0.3645 per EA.
Are there cheaper alternatives to RANOLAZINE ER 1,000 MG TABLET?
Yes. 11 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, RANOLAZINE ER 1,000 MG TABLET, is $0.2757 per EA — about 2% below RANOLAZINE ER 1,000 MG TABLET.
Who manufactures RANOLAZINE ER 1,000 MG TABLET?
RANOLAZINE ER 1,000 MG TABLET (NDC 45963041906) is labeled by Actavis Pharma, Inc., and CMS classifies it as a generic product.